Skip to main content
SpringerLink
Log in

A Risk-Benefit Assessment of Naltrexone in the Treatment of Alcohol Dependence

  • Review Article
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

There is a great deal of interest in the use of naltrexone as a treatment for alcohol (ethanol) dependence since there is a rapidly expanding body of evidence to support its efficacy and tolerability in this indication. Naltrexone, a long-acting, nonselective opioid receptor antagonist has been shown to reduce alcohol intake when combined with behavioural treatment. Naltrexone may prevent the return to clinically significant drinking by blocking the pleasurable effects or ‘high’ associated with alcohol drinking. Results from controlled studies showed that in alcohol dependent patients taking naltrexone 50 mg/day in combination with behavioural treatment, relapse rates were reduced by 50% compared with placebo treated patients.

Historically, several factors have limited the use of effective pharmacological adjuncts in the treatment of alcohol dependence. These include safety considerations in this vulnerable population, and the fact that some treatment programmes discourage alcohol-dependent patients from taking medications. The most common adverse effects reported with the use of naltrexone at a dosage of 50 mg/day include nausea and vomiting. Naltrexone does not appear to be hepatotoxic in dosages recommended in the treatment of alcohol dependence, i.e. 50 mg/day. Thus, naltrexone appears to offer significant therapeutic benefits at a relatively low risk, when used judiciously and with behavioural treatment for alcohol dependent patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Volpicelli JR, O’Brien CP, Arthur AI, et al. Naltrexone and the treatment of alcohol-dependence: initial observations. In: Reid LD, editor. Opioids, bulimia, and alcohol abuse & alcoholism. New York: Springer-Verlag, 1990

    Google Scholar 

  2. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49: 876–80

    Article  PubMed  CAS  Google Scholar 

  3. O’Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 1992; 49: 881–7

    Article  PubMed  Google Scholar 

  4. Ulm RR, Volpicelli JR, Volpicelli LA. Opiates and alcohol self-administration in animals. J Clin Psychiatry 1995; 56 (7 Suppl.): 5–14

    PubMed  Google Scholar 

  5. Froehlich JC. Genetic factors in alcohol self-administration. J Clin Psychiatry 1995; 56 (7 Suppl.): 15–23

    PubMed  Google Scholar 

  6. Volpicelli JR, Watson NT, King AC, et al. Effect of naltrexone on alcohol ‘high’ in alcoholics. Am J Psychiatry 1995; 152(4): 613–5

    PubMed  CAS  Google Scholar 

  7. Volpicelli JR. Uncontrollable events and alcohol drinking. Br J Addict 1987; 82(4): 381–92

    Article  PubMed  CAS  Google Scholar 

  8. Gianoulakis C. Endogenous opioids and excessive alcohol consumption. J Psychiatry Neurosci 1993; 18(4): 148–56

    PubMed  CAS  Google Scholar 

  9. Data on file, DuPont Merck

  10. Malcolm R, O’Neil PM, Sexauer JD, et al. A controlled trial of naltrexone in obese humans. Int J Obesity 1985; 9: 347–53

    CAS  Google Scholar 

  11. Atkinson RL, Berke LK, Drake CR, et al. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther 1985; 38(4): 419–22

    Article  PubMed  CAS  Google Scholar 

  12. Mitchell JE, Morley JE, Levine AS, et al. High dose naltrexone and dietary counselling for obesity. Biol Psychiatry 1987; 22: 35–42

    Article  PubMed  CAS  Google Scholar 

  13. Marrazzi MA, Markham KM, Kinzie J, et al. Binge eating disorder: response to naltrexone. Int J Obesity 1995; 19(2); 143–5

    CAS  Google Scholar 

  14. Pfohl DN, Allen JI, Atkinson RL, et al. Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. In: Harris LS, editor. Problems on drug dependence. Proceedings of the 47th Annual Scientific Meeting of the Committee on Problems of Alcohol Dependence, 1985 Jun 8–13. Rockville: The Committee on Problems of Drug Dependence, Inc. National Institute on Drug Abuse, Office of Science, 1986; 66–72 (National Institute on Drug Abuse Research Monograph; 67)

  15. Gillberg C. Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians. Dev Med Child Neurol 1995; 37(3): 239–45

    Article  PubMed  CAS  Google Scholar 

  16. Benjamin S, Seek A, Tresise L, et al. Case study: paradoxical response to naltrexone treatment of self-injurious behavior. J Am Acad Child Adolesc Psychiatry 1995 Feb; 34(2): 238–42

    Article  PubMed  CAS  Google Scholar 

  17. Willemsen-Swinkels SH, Buitelaar JK, Nijhof GJ, et al. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults: double-blind placebo-controlled studies. Arch Gen Psychiatry 1995; 52(9): 766–73

    Article  PubMed  CAS  Google Scholar 

  18. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a veterans administration cooperative study. JAMA 1986; 256(11): 1449–55

    Article  PubMed  CAS  Google Scholar 

  19. Ohara H, Miyabe Y, Deyashiki Y, et al. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase and aldehyde reductase of human liver. Biochem Pharmacol 1995; 50(2): 221–7

    Article  PubMed  CAS  Google Scholar 

  20. Verebey K, Volavka J, Mule SJ, et al. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 1976; 20(3): 315–28

    PubMed  CAS  Google Scholar 

  21. Dayton HE, Inturrisi CE. The urinary excretion profiles of naltrexone in man, monkey, rabbit and rat. Drug Metab Dispos 1976; 4: 474–8

    PubMed  CAS  Google Scholar 

  22. Gonzalez JP, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35: 192–213

    Article  PubMed  CAS  Google Scholar 

  23. Verebey K, Mule SJ. Naltrexone and β-naltrexol plasma levels in schizophrenic patients. Res Commun Psychol Psychiatry Behav 1979; 4(3): 311–7

    CAS  Google Scholar 

  24. Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman & Gilman’s pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996

    Google Scholar 

  25. Kleber HD, Kosten TR, Gaspari J, et al. Nontolerance to the opioid antagonism of naltrexone. Biol Psychiatry 1985; 20: 66–72

    Article  PubMed  CAS  Google Scholar 

  26. Kosten TR, Kreek MJ, Ragunath J, et al. Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. Biol Psychiatry 1986; 21: 217–20

    Article  PubMed  CAS  Google Scholar 

  27. Volavka J, Mallya A, Bauman J, et al. Hormonal and other effects of naltrexone in normal men. Adv Exp Med Biol 1979; 116: 291–305

    PubMed  CAS  Google Scholar 

  28. Kosten TR, Kreek MJ, Ragunath J, et al. A preliminary study of β-endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life Sci 1986; 39: 55–9

    Article  PubMed  CAS  Google Scholar 

  29. Mendelson JH, Ellingboe J, Keuhnle JC, et al. Effects of naltrexone on mood and neuroendocrine function in normal adult males. Psychoneuroendocrinology 1978; 3: 231–6

    Article  PubMed  CAS  Google Scholar 

  30. Mendelson JH, Ellingboe J, Kuehnle JC, et al. Heroin and naltrexone effects on pituitary-gonadal hormones in man: interaction of steroid feedback effects, tolerance and super-sensitivity. J Pharmacol Exp Ther 1980; 214: 503–6

    PubMed  CAS  Google Scholar 

  31. Mendelson JH, Mello NK, Cristofaro P, et al. Use of naltrexone as a provocative test for hypothalamic-pituitary hormone function. Pharmacol Biochem Behav 1986; 24: 309–13

    Article  PubMed  CAS  Google Scholar 

  32. Mirin SM, Mendelson JH, Ellingboe J, et al. Acute effects of heroin and naltrexone on testosterone and gonadotropin secretion: a pilot study. Psychoneuroendocrinology 1976; 1: 359–69

    Article  Google Scholar 

  33. Ellingboe J, Mendelson JH, Kuehnle JC. Effects of heroin and naltrexone on plasma prolactin levels in man. Pharmacol Biochem Behav 1980; 12: 163–5

    Article  PubMed  CAS  Google Scholar 

  34. Wildt L, Leyendecker G. Induction of ovulation by the chronic administration of naltrexone in hypothalamic amenorrhea. J Clin Endocrinol Metab 1987; 64(6): 1334–5

    Article  PubMed  CAS  Google Scholar 

  35. Keshet GI, Weinstock M. Maternal naltrexone prevents morphological and behavioral alterations induced in rats by prenatal stress. Pharmacol Biochem Behav 1995; 50(3): 413–9

    Article  PubMed  CAS  Google Scholar 

  36. Maestroni G, Conti A, Pierpaoli W. Role of the pineal gland in immunity: II. Melatonin enhances the antibody response via an opiatergic mechanism. Clin Exp Immunol 1987; 68: 384–91

    PubMed  CAS  Google Scholar 

  37. Crowley TJ, Wagner JE, Zerbe G, et al. Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry 1985; 142(9): 1081–4

    PubMed  CAS  Google Scholar 

  38. Brahen LS, Capone TJ, Capone DM. Naltrexone: lack of effect on hepatic enzymes. J Clin Pharmacol 1988; 28: 64–70

    PubMed  CAS  Google Scholar 

  39. Greenstein RA, Resnick RB, Resnick E. Methadone and naltrexone in the treatment of heroin dependence. Psychiatr Clin North Am 1984; 7(4): 671–9

    PubMed  CAS  Google Scholar 

  40. Lee MC, Wagner HN, Tanada S, et al. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 1988; 29(7): 1207–11

    PubMed  CAS  Google Scholar 

  41. Maany I, O’Brien CP, Woody G. Interaction between thioridazine and naltrexone [letter]. Am J Psychiatry 1987; 144(7): 966

    PubMed  CAS  Google Scholar 

  42. Gilmore R, Hack R, Kuhn R, et al. Naltrexone-associated decrease in phenytoin concentration [letter]. Epilepsia 1989; 3(5): 738

    Google Scholar 

  43. Marrazzi MA, Jacober S, Luby ED. A naltrexone-induced increase in insulin requirement. J Clin Psychopharmacol 1994; 14(5): 363–5

    PubMed  CAS  Google Scholar 

  44. Physicians’ Desk Reference. 50th ed. Montvale (NJ): Medical Economics Co., 1996

Download references

Author information

Authors and Affiliations

  1. Addiction Treatment Research Center, University of Pennsylvania, 3900 Chestnut Street, Philadelphia, Pennsylvania, 19104, USA

    Bruce J. Berg, Helen M. Pettinati &  Joseph R. Volpicelli

Authors
  1. Bruce J. Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helen M. Pettinati
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph R. Volpicelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph R. Volpicelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berg, B.J., Pettinati, H.M. & Volpicelli, J.R. A Risk-Benefit Assessment of Naltrexone in the Treatment of Alcohol Dependence. Drug-Safety 15, 274–282 (1996). https://doi.org/10.2165/00002018-199615040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199615040-00005

Keywords

Search

Navigation